標(biāo)題: Titlebook: Chemotherapy in Neonates and Infants; Pharmacological Onco Carolina Witchmichen Penteado Schmidt Book 2018 Springer International Publishin [打印本頁(yè)] 作者: 浮華 時(shí)間: 2025-3-21 18:45
書(shū)目名稱Chemotherapy in Neonates and Infants影響因子(影響力)
書(shū)目名稱Chemotherapy in Neonates and Infants影響因子(影響力)學(xué)科排名
書(shū)目名稱Chemotherapy in Neonates and Infants網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Chemotherapy in Neonates and Infants網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Chemotherapy in Neonates and Infants被引頻次
書(shū)目名稱Chemotherapy in Neonates and Infants被引頻次學(xué)科排名
書(shū)目名稱Chemotherapy in Neonates and Infants年度引用
書(shū)目名稱Chemotherapy in Neonates and Infants年度引用學(xué)科排名
書(shū)目名稱Chemotherapy in Neonates and Infants讀者反饋
書(shū)目名稱Chemotherapy in Neonates and Infants讀者反饋學(xué)科排名
作者: 百科全書(shū) 時(shí)間: 2025-3-21 22:46
https://doi.org/10.1007/978-3-642-29511-9ted here are referenced in the final section of this book. Protocols may vary according to each institution. It is important to know every drug used in the protocol, to take the necessary care, and to perform the necessary examinations to avoid collateral effects and toxicity. The protocols for neon作者: 避開(kāi) 時(shí)間: 2025-3-22 02:50 作者: Monotonous 時(shí)間: 2025-3-22 06:35 作者: 四牛在彎曲 時(shí)間: 2025-3-22 10:32 作者: Urea508 時(shí)間: 2025-3-22 15:20
Model Risk and Parameter Sensitivityemias—with a 10- to 20-fold increased risk of developing this kind of disease—they have a markedly decreased incidence of solid tumors. These patients also have a particular profile of treatment-related toxicities [72, 73].作者: Urea508 時(shí)間: 2025-3-22 18:42 作者: Estimable 時(shí)間: 2025-3-23 00:31
http://image.papertrans.cn/c/image/224971.jpg作者: 北極人 時(shí)間: 2025-3-23 03:49
Quantifying Input Quality Aspects,etion. Basically, pharmacokinetics involves the way that the drug goes through after it enters the body, whereas pharmacodynamics involves what the drug does in the body, i.e., the mechanism of action of the drug [1].作者: alleviate 時(shí)間: 2025-3-23 07:46
Model Risk and Parameter Sensitivityemias—with a 10- to 20-fold increased risk of developing this kind of disease—they have a markedly decreased incidence of solid tumors. These patients also have a particular profile of treatment-related toxicities [72, 73].作者: Bucket 時(shí)間: 2025-3-23 11:31 作者: 敘述 時(shí)間: 2025-3-23 16:09
https://doi.org/10.1007/978-3-642-29721-2There have been few studies of drugs used in neonates and infants. Ninety percent of all off-label drug prescriptions are used in neonatology [101].作者: 無(wú)王時(shí)期, 時(shí)間: 2025-3-23 20:57
Model Risk and Parameter SensitivityCommonly, pediatric hemato-oncologists are not accustomed to the peculiarities of drug therapy in neonatology, and so they need to pay attention to the issue of drug excipients—just as they should pay attention to avoiding preservative administration to neonates and infants.作者: incredulity 時(shí)間: 2025-3-24 01:44 作者: septicemia 時(shí)間: 2025-3-24 04:50
Peculiarities of Most Commonly Used Chemotherapy Drugs in Neonates and Infants,This description of drugs, doses, and other information is provided for study. Broad knowledge of the drug, the protocol (drug dosages vary a lot according to different protocols), toxicity, dose adjustment, patient monitoring, and other pertinent aspects is necessary before prescribing.作者: Paradox 時(shí)間: 2025-3-24 07:38 作者: Spinal-Tap 時(shí)間: 2025-3-24 13:38
Toxicity,Commonly, pediatric hemato-oncologists are not accustomed to the peculiarities of drug therapy in neonatology, and so they need to pay attention to the issue of drug excipients—just as they should pay attention to avoiding preservative administration to neonates and infants.作者: 爆米花 時(shí)間: 2025-3-24 17:35 作者: TAIN 時(shí)間: 2025-3-24 22:49
https://doi.org/10.1007/978-3-319-70591-0Pediatric oncohematology; Chemotherapy; Newborn; Neonate; Infants; Pharmacology作者: Melodrama 時(shí)間: 2025-3-24 23:55 作者: 松果 時(shí)間: 2025-3-25 05:47 作者: moribund 時(shí)間: 2025-3-25 07:42
Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and Hemias—with a 10- to 20-fold increased risk of developing this kind of disease—they have a markedly decreased incidence of solid tumors. These patients also have a particular profile of treatment-related toxicities [72, 73].作者: characteristic 時(shí)間: 2025-3-25 15:33
Introduction,as in most references about neonates and infants, the word “neonate” refers to a baby up to 28 days after birth [3]. If a neonate is born prematurely, he can still be called by this terminology—neonate—if he was born more than 28 days previously but his postmenstrual age is ≤42–46 weeks. A baby who 作者: 懦夫 時(shí)間: 2025-3-25 17:18
Protocols Used in Chemotherapy Treatment of Neonates and Infants,ted here are referenced in the final section of this book. Protocols may vary according to each institution. It is important to know every drug used in the protocol, to take the necessary care, and to perform the necessary examinations to avoid collateral effects and toxicity. The protocols for neon作者: 要塞 時(shí)間: 2025-3-25 20:49 作者: Leaven 時(shí)間: 2025-3-26 00:51
Drug Interactions in Neonates and Infants,hese patients. It is widely published that cow’s milk contains a high level of xanthine oxidase enzyme, which can interact with 6-mercaptopurine; this interaction is clinically significant. 6-Mercaptopurine is catabolized by xanthine oxidase to the inactive metabolite 6-thiouric acid. It is recommen作者: 節(jié)約 時(shí)間: 2025-3-26 04:43
Tumor Lysis in Neonates and Infants,erphosphatemia. Hyperphosphatemia may lead to hypocalcemia. Tumor lysis syndrome usually develops after the start of chemotherapy and may lead to acute renal failure and death, due to renal tubular precipitation of uric acid and other complications. The risk factors for development of tumor lysis sy作者: 抵押貸款 時(shí)間: 2025-3-26 08:29
Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and Hemias—with a 10- to 20-fold increased risk of developing this kind of disease—they have a markedly decreased incidence of solid tumors. These patients also have a particular profile of treatment-related toxicities [72, 73].作者: 比目魚(yú) 時(shí)間: 2025-3-26 16:14 作者: FRET 時(shí)間: 2025-3-26 17:37 作者: DAMN 時(shí)間: 2025-3-26 23:28
otocols and management of drugs for each week/month of life This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily cli作者: bacteria 時(shí)間: 2025-3-27 02:09 作者: 楓樹(shù) 時(shí)間: 2025-3-27 08:02 作者: Lipoprotein(A) 時(shí)間: 2025-3-27 12:41 作者: 高腳酒杯 時(shí)間: 2025-3-27 14:51
Introduction to Asset-Backed Securitiesith its activity in bovine milk, xanthine oxidase in human milk has extremely low specific activity in all assays with reducing substrates other than reduced nicotinamide ad enine dinucleotide (NADH) [1, 92, 93].作者: fetter 時(shí)間: 2025-3-27 19:11 作者: 有惡意 時(shí)間: 2025-3-27 22:24 作者: 未完成 時(shí)間: 2025-3-28 04:36 作者: 可能性 時(shí)間: 2025-3-28 09:28
Book 2018 at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacistsand the other healthcare professionals directly involved in the chemotherapy of neonates and infants..?.作者: Inflammation 時(shí)間: 2025-3-28 12:37
Tumor Lysis in Neonates and Infants,ndrome are malignancies with large growth fraction (i.e. B-cell and T-cell lymphomas/leukemias), large tumor bulk, use of cytolytic chemotherapy, pre-existing renal insufficiency, kidney involvement, ureteral or bladder obstruction by the tumor, and metabolic abnormalities [95].作者: 橡子 時(shí)間: 2025-3-28 15:55
8樓作者: Ligament 時(shí)間: 2025-3-28 18:59
9樓作者: 表臉 時(shí)間: 2025-3-28 23:01
9樓作者: 溫室 時(shí)間: 2025-3-29 04:19
9樓作者: BLANK 時(shí)間: 2025-3-29 11:01
9樓作者: POINT 時(shí)間: 2025-3-29 11:33
10樓作者: aggressor 時(shí)間: 2025-3-29 18:11
10樓作者: Monocle 時(shí)間: 2025-3-29 23:44
10樓作者: Acquired 時(shí)間: 2025-3-30 02:07
10樓
